2025 Q4 -tulosraportti
49 päivää sitten
‧31 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 15.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 17.3. | ||
2025 Q3 -tulosraportti 4.11.2025 | ||
2025 Q2 -tulosraportti 13.8.2025 | ||
Vuosittainen yhtiökokous 2025 13.6.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·9.4.New Chinese patent strengthens Longeveron's global position. Longeveron continues to build a strong foundation for the future. On April 8, 2026, the company announced that it had been granted a Chinese patent for a key method to test the strength ("potency") of mesenchymal stem cells (MSC). This is not just a technical detail – it is a strategic milestone that could be of great importance for the company's future revenues, competitive advantages, and global expansion. What is it about? The new patent protects a method for ensuring the quality of the stem cells used in Longeveron's therapies. It applies to MSC from several different sources (bone marrow, adipose tissue, umbilical cord, etc.) and is valid in China until 2041. Since such tests are crucial for obtaining regulatory approval of cell therapies, this is an important step to secure Longeveron's technology in one of the world's largest markets. Why is this important? This is Longeveron's 52nd patent globally – a clear sign that the company is building a broad and robust intellectual property portfolio. It strengthens the company's negotiating position in future partnerships, protects against competitors, and opens doors to licensing revenues. In China, where interest in regenerative medicine is growing rapidly, this patent could become a key to future collaborations or market entry. Bright spots ahead: • The HLHS program (a rare heart disease in newborns) is in Phase 2b and is expected to report results in Q3 2026. With positive data, a BLA application to the FDA could be submitted as early as 2027. • Laromestrocel has received five important FDA designations (including Orphan Drug, Fast Track, and RMAT), which can accelerate the approval process and provide market exclusivity. • Upon approval of the HLHS therapy, Longeveron could receive a so-called Priority Review Voucher (PRV), which can be sold for up to 200 million USD – a potential game changer for the company's finances. • The Alzheimer's program has shown promising results in Phase 2a and has regulatory support to proceed towards a registrational study. • The company has a clear strategy to seek partnerships to scale up and commercialize its therapies – something that can reduce capital requirements and increase reach. Conclusion: The Chinese patent is more than just a legal formality – it is proof of Longeveron's long-term strategy to build a global safety net around its technology. Together with strong clinical data, regulatory advantages, and a growing pipeline, Longeveron positions itself as a serious player in regenerative medicine. For us shareholders, this means that the company is taking important steps towards realizing its commercial value.- ·18.3.Longeveron's press release on March 17, 2026, shows that the company is facing a pivotal year. The most exciting thing is that in Q3 2026, we will receive results from the phase 2b study ELPIS II for the treatment of HLHS – a rare and fatal heart disease in infants. Previous phase 1 data showed 100 % survival after 5 years, which is far above historical figures. If phase 2b confirms this, Longeveron can submit a BLA application in 2027 and receive a PRV (Priority Review Voucher) worth up to 200 MUSD – a potential gamechanger. Financially, 2025 was tough: revenues halved to 1.2 MUSD and the loss increased to 22.7 MUSD. But in March 2026, 15 MUSD in new financing was secured from major investors like Coastlands Capital and Janus Henderson, which extends the cash runway to Q4 2026 – i.e., beyond the HLHS results. In addition to HLHS, Longeveron has promising programs in Alzheimer's and pediatric heart failure (PDCM). The AD program has been published in Nature Medicine and has FDA's RMAT and Fast Track status. The PDCM program is expected to start phase 2 in 2027. Furthermore, the company has shown positive results in a phase 2b study for age-related frailty. The strategy is clear: focus on partnerships to reduce capital requirements and accelerate the path to market. With several potential triggers in 2026–2027, a strong scientific foundation, and a low valuation (~20 MUSD), there are good opportunities for revaluation if the HLHS program succeeds. In summary: high risk, but also high potential. The HLHS results in Q3 2026 will be decisive. If successful, Longeveron can take a big step towards becoming a commercial company with a life-saving product on the market. Conclusion: despite these risks, Longeveron – in light of the press release – appears as a company where several lights are currently appearing at the end of the tunnel. It has survived a tough period, secured capital, strengthened its team, and is soon reaching the clinical “finish line” for the first program. 2026 will be a pivotal year: a positive HLHS result can transform the company from a research company into a future producer of life-saving treatment. At the same time, the platform is being expanded towards larger indications, which provides “extra tickets” in the portfolio. For shareholders, this press release means that the company is entering the next phase with better conditions than for a long time – there are reasons for cautious optimism. With critical data around the corner, a clear partnering strategy, and support from new investors, Longeveron has now set the stage for potentially value-creating events. Now it's just a matter of delivering in the laboratory and clinic – if successful there, the upward journey for the stock may have just begun.
·10.3.Now there damn well needs to be some serious action soon.
·11.3.Would have liked to see over 0.91
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
49 päivää sitten
‧31 min
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·9.4.New Chinese patent strengthens Longeveron's global position. Longeveron continues to build a strong foundation for the future. On April 8, 2026, the company announced that it had been granted a Chinese patent for a key method to test the strength ("potency") of mesenchymal stem cells (MSC). This is not just a technical detail – it is a strategic milestone that could be of great importance for the company's future revenues, competitive advantages, and global expansion. What is it about? The new patent protects a method for ensuring the quality of the stem cells used in Longeveron's therapies. It applies to MSC from several different sources (bone marrow, adipose tissue, umbilical cord, etc.) and is valid in China until 2041. Since such tests are crucial for obtaining regulatory approval of cell therapies, this is an important step to secure Longeveron's technology in one of the world's largest markets. Why is this important? This is Longeveron's 52nd patent globally – a clear sign that the company is building a broad and robust intellectual property portfolio. It strengthens the company's negotiating position in future partnerships, protects against competitors, and opens doors to licensing revenues. In China, where interest in regenerative medicine is growing rapidly, this patent could become a key to future collaborations or market entry. Bright spots ahead: • The HLHS program (a rare heart disease in newborns) is in Phase 2b and is expected to report results in Q3 2026. With positive data, a BLA application to the FDA could be submitted as early as 2027. • Laromestrocel has received five important FDA designations (including Orphan Drug, Fast Track, and RMAT), which can accelerate the approval process and provide market exclusivity. • Upon approval of the HLHS therapy, Longeveron could receive a so-called Priority Review Voucher (PRV), which can be sold for up to 200 million USD – a potential game changer for the company's finances. • The Alzheimer's program has shown promising results in Phase 2a and has regulatory support to proceed towards a registrational study. • The company has a clear strategy to seek partnerships to scale up and commercialize its therapies – something that can reduce capital requirements and increase reach. Conclusion: The Chinese patent is more than just a legal formality – it is proof of Longeveron's long-term strategy to build a global safety net around its technology. Together with strong clinical data, regulatory advantages, and a growing pipeline, Longeveron positions itself as a serious player in regenerative medicine. For us shareholders, this means that the company is taking important steps towards realizing its commercial value.
- ·18.3.Longeveron's press release on March 17, 2026, shows that the company is facing a pivotal year. The most exciting thing is that in Q3 2026, we will receive results from the phase 2b study ELPIS II for the treatment of HLHS – a rare and fatal heart disease in infants. Previous phase 1 data showed 100 % survival after 5 years, which is far above historical figures. If phase 2b confirms this, Longeveron can submit a BLA application in 2027 and receive a PRV (Priority Review Voucher) worth up to 200 MUSD – a potential gamechanger. Financially, 2025 was tough: revenues halved to 1.2 MUSD and the loss increased to 22.7 MUSD. But in March 2026, 15 MUSD in new financing was secured from major investors like Coastlands Capital and Janus Henderson, which extends the cash runway to Q4 2026 – i.e., beyond the HLHS results. In addition to HLHS, Longeveron has promising programs in Alzheimer's and pediatric heart failure (PDCM). The AD program has been published in Nature Medicine and has FDA's RMAT and Fast Track status. The PDCM program is expected to start phase 2 in 2027. Furthermore, the company has shown positive results in a phase 2b study for age-related frailty. The strategy is clear: focus on partnerships to reduce capital requirements and accelerate the path to market. With several potential triggers in 2026–2027, a strong scientific foundation, and a low valuation (~20 MUSD), there are good opportunities for revaluation if the HLHS program succeeds. In summary: high risk, but also high potential. The HLHS results in Q3 2026 will be decisive. If successful, Longeveron can take a big step towards becoming a commercial company with a life-saving product on the market. Conclusion: despite these risks, Longeveron – in light of the press release – appears as a company where several lights are currently appearing at the end of the tunnel. It has survived a tough period, secured capital, strengthened its team, and is soon reaching the clinical “finish line” for the first program. 2026 will be a pivotal year: a positive HLHS result can transform the company from a research company into a future producer of life-saving treatment. At the same time, the platform is being expanded towards larger indications, which provides “extra tickets” in the portfolio. For shareholders, this press release means that the company is entering the next phase with better conditions than for a long time – there are reasons for cautious optimism. With critical data around the corner, a clear partnering strategy, and support from new investors, Longeveron has now set the stage for potentially value-creating events. Now it's just a matter of delivering in the laboratory and clinic – if successful there, the upward journey for the stock may have just begun.
- ·10.3.Now there damn well needs to be some serious action soon.·11.3.Would have liked to see over 0.91
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 15.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 17.3. | ||
2025 Q3 -tulosraportti 4.11.2025 | ||
2025 Q2 -tulosraportti 13.8.2025 | ||
Vuosittainen yhtiökokous 2025 13.6.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
2025 Q4 -tulosraportti
49 päivää sitten
‧31 min
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 15.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 17.3. | ||
2025 Q3 -tulosraportti 4.11.2025 | ||
2025 Q2 -tulosraportti 13.8.2025 | ||
Vuosittainen yhtiökokous 2025 13.6.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·9.4.New Chinese patent strengthens Longeveron's global position. Longeveron continues to build a strong foundation for the future. On April 8, 2026, the company announced that it had been granted a Chinese patent for a key method to test the strength ("potency") of mesenchymal stem cells (MSC). This is not just a technical detail – it is a strategic milestone that could be of great importance for the company's future revenues, competitive advantages, and global expansion. What is it about? The new patent protects a method for ensuring the quality of the stem cells used in Longeveron's therapies. It applies to MSC from several different sources (bone marrow, adipose tissue, umbilical cord, etc.) and is valid in China until 2041. Since such tests are crucial for obtaining regulatory approval of cell therapies, this is an important step to secure Longeveron's technology in one of the world's largest markets. Why is this important? This is Longeveron's 52nd patent globally – a clear sign that the company is building a broad and robust intellectual property portfolio. It strengthens the company's negotiating position in future partnerships, protects against competitors, and opens doors to licensing revenues. In China, where interest in regenerative medicine is growing rapidly, this patent could become a key to future collaborations or market entry. Bright spots ahead: • The HLHS program (a rare heart disease in newborns) is in Phase 2b and is expected to report results in Q3 2026. With positive data, a BLA application to the FDA could be submitted as early as 2027. • Laromestrocel has received five important FDA designations (including Orphan Drug, Fast Track, and RMAT), which can accelerate the approval process and provide market exclusivity. • Upon approval of the HLHS therapy, Longeveron could receive a so-called Priority Review Voucher (PRV), which can be sold for up to 200 million USD – a potential game changer for the company's finances. • The Alzheimer's program has shown promising results in Phase 2a and has regulatory support to proceed towards a registrational study. • The company has a clear strategy to seek partnerships to scale up and commercialize its therapies – something that can reduce capital requirements and increase reach. Conclusion: The Chinese patent is more than just a legal formality – it is proof of Longeveron's long-term strategy to build a global safety net around its technology. Together with strong clinical data, regulatory advantages, and a growing pipeline, Longeveron positions itself as a serious player in regenerative medicine. For us shareholders, this means that the company is taking important steps towards realizing its commercial value.
- ·18.3.Longeveron's press release on March 17, 2026, shows that the company is facing a pivotal year. The most exciting thing is that in Q3 2026, we will receive results from the phase 2b study ELPIS II for the treatment of HLHS – a rare and fatal heart disease in infants. Previous phase 1 data showed 100 % survival after 5 years, which is far above historical figures. If phase 2b confirms this, Longeveron can submit a BLA application in 2027 and receive a PRV (Priority Review Voucher) worth up to 200 MUSD – a potential gamechanger. Financially, 2025 was tough: revenues halved to 1.2 MUSD and the loss increased to 22.7 MUSD. But in March 2026, 15 MUSD in new financing was secured from major investors like Coastlands Capital and Janus Henderson, which extends the cash runway to Q4 2026 – i.e., beyond the HLHS results. In addition to HLHS, Longeveron has promising programs in Alzheimer's and pediatric heart failure (PDCM). The AD program has been published in Nature Medicine and has FDA's RMAT and Fast Track status. The PDCM program is expected to start phase 2 in 2027. Furthermore, the company has shown positive results in a phase 2b study for age-related frailty. The strategy is clear: focus on partnerships to reduce capital requirements and accelerate the path to market. With several potential triggers in 2026–2027, a strong scientific foundation, and a low valuation (~20 MUSD), there are good opportunities for revaluation if the HLHS program succeeds. In summary: high risk, but also high potential. The HLHS results in Q3 2026 will be decisive. If successful, Longeveron can take a big step towards becoming a commercial company with a life-saving product on the market. Conclusion: despite these risks, Longeveron – in light of the press release – appears as a company where several lights are currently appearing at the end of the tunnel. It has survived a tough period, secured capital, strengthened its team, and is soon reaching the clinical “finish line” for the first program. 2026 will be a pivotal year: a positive HLHS result can transform the company from a research company into a future producer of life-saving treatment. At the same time, the platform is being expanded towards larger indications, which provides “extra tickets” in the portfolio. For shareholders, this press release means that the company is entering the next phase with better conditions than for a long time – there are reasons for cautious optimism. With critical data around the corner, a clear partnering strategy, and support from new investors, Longeveron has now set the stage for potentially value-creating events. Now it's just a matter of delivering in the laboratory and clinic – if successful there, the upward journey for the stock may have just begun.
- ·10.3.Now there damn well needs to be some serious action soon.·11.3.Would have liked to see over 0.91
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt